Steroid Diabetes in Patients With Kidney Disease
ConditionNephrotic Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorZhejiang Provincial People's Hospital
About this trial
If steroid diabetes is not recognized in time, it will cause irreversible damage to the body. Nephropathy patients are more likely to have steroid diabetes ,the incidence rate up to 25%,due to hypoalbuminemia, high-dose hormone and other reasons, so they need to be closely followed up, identified and intervened in time.
Eligibility criteria
Qualifiers
Patients who need to use glucocorticoids due to the following diseases: nephrotic syndrome, Immunoglobulin A nephropathy, membranous nephropathy, Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus；
Initial daily dose of glucocorticoids greater than or equal to 10mg of prednisolone；
Disqualifiers
Patients with diabetes；
Those who are unable to communicate through language；
Uremic patients；
Unable to perform blood glucose monitoring and follow-up as required；
Trial design
Treatments tested in this trial
- no intervention
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
1Zhejiang provincial people's hospital0571, HangzhouZhejiang, China
Sponsors and collaborators
Zhejiang Provincial People's Hospital
Lead sponsor
The Third Affiliated Hospital of Wenzhou Medical University
Collaborator
The First People's Hospital of Xiaoshan District, Hangzhou City
Collaborator
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Collaborator
Nanxun District People's Hospital of Huzhou City，China
Collaborator
Wenling Traditional Chinese Medicine Hospital
Collaborator
Affiliated Hospital of Jiaxing University
Collaborator
Taizhou Hospital
Collaborator
The First People's Hospital of Chun'an
Collaborator
Source ClinicalTrials.gov